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This study explored attitudes toward hypothetical genetic testing for posttraumatic 
stress disorder (PTSD) and addiction among veterans. We surveyed a random sample 
of community-based veterans (n =  700) by telephone. One year later, we asked the 
veterans to provide a DNA sample for analysis and 41.9% of them returned the DNA 
samples. Overall, most veterans were not interested in genetic testing neither for PTSD 
(61.7%) nor for addiction (68.7%). However, bivariate analyses suggested there was 
an association between having the condition of interest and the likelihood of genetic 
testing on a 5-point scale (p < 0.001 for PTSD; p = 0.001 for alcohol dependence). 
While ordinal regressions confirmed these associations, the models with the best sta-
tistical fit were bivariate models of whether the veteran would likely test or not. Using 
logistic regressions, significant predictors for PTSD testing were receiving recent mental 
health treatment, history of a concussion, younger age, having PTSD, having alcohol 
dependence, currently taking opioids for pain, and returning the DNA sample during 
the follow-up. For addiction testing, significant predictors were history of concussion, 
younger age, psychotropic medication use, having alcohol dependence, and currently 
taking opioids for pain. Altogether, 25.9% of veterans reported that they would have 
liked to have known their genetic results before deployment, 15.6% reported after 
deployment, and 58.6% reported they did not want to know neither before nor after 
deployment. As advancements in genetic testing continue to evolve, our study suggests 
that consumer attitudes toward genetic testing for mental disorders are complex and 
better understanding of these attitudes and beliefs will be crucial to successfully promote 
utilization.
Keywords: genetic testing, posttraumatic stress disorder, addiction, veterans, psychiatric genetics
inTrODUcTiOn
Understanding of the genetic bases of psychiatric disorders continues to improve, despite the 
complexity and various gene–environment interactions that can influence such behaviors (1). The 
potential benefits of genetic testing may include better diagnostic screening, early prevention and, in 
the case of Mendelian genetic disorders, the ability to make more informed reproductive decisions 
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(2, 3). Conversely, genetic testing could impact well-being (4, 5), 
raise the potential for discrimination (2, 3), and cause conflict 
within families (4). Questions surrounding privacy, as well as 
who should be tested and why, also present multifaceted dilem-
mas (2, 4). Genetic testing for psychiatric disorder risk is likely 
to become increasingly incorporated into clinical practice in the 
future, especially as more direct-to-consumer testing products 
become available (6).
A review of studies on general consumer attitudes surround-
ing genetic testing for psychiatric disorders identified several 
areas for future study: specifically, the need to study individuals 
without psychiatric disorders or not involved in genetics-related 
research, and the need for larger samples (2). Only one study to 
date has evaluated veterans’ attitudes toward psychiatric disorder 
genetic testing (7). This study found that veterans with posttrau-
matic stress disorder (PTSD) viewed genetic testing for PTSD less 
favorably than those without PTSD and were more likely to fear 
insurance discrimination.
Attitudes toward genetic testing for psychiatric disorders 
among military veterans are largely unknown despite the high 
prevalence of certain psychiatric disorders among veterans and 
the regular screening of patients at VA facilities for psychiatric 
disorders, including PTSD and addiction (8, 9). Prevalence 
estimates of PTSD range from 10% in male Gulf War veterans 
to 15% in Vietnam-era male veterans, compared to 3.6% of 
males in the general population (10–13). Additionally, 2 out 
of every 10 veterans with PTSD also live with substance use 
disorders (13).
Consumer attitudes toward genetic testing for psychiatric 
disorders are mixed (3, 5, 7). In one study, 83% of family mem-
bers of individuals with schizophrenia reported interest in 
genetic testing for this condition (14). Additionally, individu-
als with a family history of bipolar disorder generally endorsed 
that they would pursue genetic testing if the assessment has 
high diagnostic certainty, but fewer wanted their children 
tested at birth (3). Unaffected relatives of individuals with 
psychiatric disorders emphasized the importance of genetic 
counseling prior to testing to provide consumers with an accu-
rate assessment of potential risk in the context of reproductive 
decision-making (15). Consumers with psychiatric disorders 
not only reported interest in contributing to genetic research 
but also reported concerns regarding having to make “difficult 
choices,” the perception of certain lives as more valuable than 
others, and the possibility of discrimination (5). Individuals 
with alcohol use disorders were willing to provide genetic 
samples but also expressed concerns surrounding health 
insurance denial, employment discrimination, and identity 
theft (16).
In this study, we randomly surveyed a cohort of 700 commu-
nity-based U.S. military veterans with and without psychiatric 
disorders regarding their attitudes about hypothetical genetic 
testing at baseline for PTSD and addiction. All study veterans 
served at least one warzone deployment and were considered to 
be at risk for these conditions post deployment (17). One year 
later, we recontacted these veterans and asked them to return a 
DNA sample for genetic analyses.
MaTerials anD MeThODs
Participants
The study cohort included a random sample of community-based 
U.S. military veterans (n =  700) recruited as part of a broader 
study of the health effects of military service (18). For our sample, 
we created a computer-generated random number, which was 
then assigned to each veteran identified in our Health System. 
Based on this number, patients were randomly selected for survey 
interviews. All participants were outpatients in the multihospital 
system and self-identified as veterans, which was verified during 
the survey recruitment. Veterans with and without psychiatric 
disorders were interviewed.
Inclusion criteria were English-speaking, had one or more 
deployments in a warzone, and had an age less than 75  years. 
Institutionalization and an inability to complete a 45-min inter-
view were exclusion criteria. The study participation rate was 
estimated to be 65% (19). The Health System’s Institutional Review 
Board approved the study protocol, and all participants provided 
verbal informed consent for the baseline phone survey and written 
consent for the DNA sample at follow-up. A small incentive was 
provided to complete the survey ($15) and to return the DNA 
sample by mail ($15).
Telephone interviews
The interviews were administered by telephone by trained mental 
health interviewers working in a supervised, professional survey 
research center from December 2011 through January 2012. The 
survey instruments utilized were used in previous studies (20–25) 
and validated in national and regional trauma studies involving 
over 30,000 respondents exposed to psychological trauma (24, 
26). Comparison of telephone vs. in-person surveys using survey 
instruments suggests similar results in mental health studies 
(27, 28).
Participants provided information on military service branch, 
deployment history, smoking history, mental health history, con-
cussion history, and other demographic and medical information 
(18). They were also screened for probable alcohol dependence 
using the CAGE (Cut Down, Annoyed, Guilty, and Eye Opener) 
questionnaire (29). Combat exposure was assessed using a ver-
sion of the Combat Experience Scale (30).
Participants answered questions regarding their attitudes 
toward hypothetical genetic testing at baseline for PTSD and 
addiction after the following introduction was provided: “Genetic 
tests are being developed for different medical problems. Soon 
genetic tests may be available to predict a person’s risks for addic-
tion and posttraumatic stress disorder. If such genetic tests were 
available, how likely would you be to have this genetic test?” This 
question was assessed on a 5-point Likert Scale, ranging from 
“extremely likely” to “not likely at all.” Following this question, 
they were asked two open-ended questions about their answers 
to these Likert-scaled questions (i.e., “Why did you respond 
like you did for addiction?”). Participants were also asked when 
they would have liked to have known their genetic risks (i.e., 
before deployment, after or neither before or after deployment). 
Measures of trust, discrimination, and concerns about privacy 
TaBle 1 | sample characteristics (N = 700).
study variables n (%)
age
18–39 66 (9.4)
40–64 415 (59.3)
65+ 219 (31.3)
Male 671 (95.9)
White race 653 (93.3)
Married 557 (79.6)
Employed full-time or part-time 313 (44.7)
Have health-care insurance 674 (96.3)
Some college or higher 399 (57.0)
Multiple warzone deployments 200 (28.6)
Currently use VA for health care 283 (40.4)
Received mental health treatment, past year 153 (21.9)
Reports poor/fair current health 221 (31.6)
Returned DNA sample 293 (41.9)
Warzone service
Vietnam 504 (72.0)
Gulf war 68 (9.7)
Iraq/Afghanistan 96 (13.7)
Other 32 (4.6)
substance use/medication use/combat
Smoked 100+ cigarettes in lifetime 505 (72.1)
Drank nearly every day in past year 66 (9.4)
Heavy drinking in the past 30 days 83 (11.9)
Alcohol dependence in past yeara 87 (12.4)
Used psychotropic medications in past year 144 (20.6)
Used prescription painkillers in past year 97 (13.9)
Combat was major traumatic event 569 (82.3)
High combat exposure history 148 (21.1)
History of concussion during deployment 181 (25.9)
Psychiatric disorders
Lifetime posttraumatic stress disorder (PTSD) 67 (9.6)
PTSD in past year 47 (6.7)
Subclinical PTSD in the past yearb 109 (15.6)
Lifetime major depression disorder 129 (18.4)
Major depression in past year 44 (6.2)
aCAGE questionnaire (29).
bBreslau criteria for PTSD (35).
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were not explicitly assessed in the current survey. However, we 
did use open-ended survey questions as a way to capture the 
concerns of veterans, as is commonly done in behavioral research 
(31, 32). We inquired about health insurance status, employment 
status, and use of VA services to add to our analyses to assess the 
impact of these variables on testing responses.
Our open-ended questions were administered and coded 
in accordance with standard procedures for survey research 
(31, 32). Open-ended questions were recorded verbatim during 
the interview. Each question was probed up to three times for 
specificity, if necessary. For instance, if a vague response was 
given (e.g., “it depends …”), the interviewer probed the respond-
ent to be more specific. After survey completion, the verbatim 
responses were manually coded. Following this, tabulations were 
compiled and coding was revised in consultation the with study 
Principal Investigator to capture any new categories that emerged 
or to collapse existing categories (31, 32).
Dna sample collection
Approximately 1 year after the survey, veterans were recontacted 
and asked to provide a DNA sample using Orogene DNA kits 
manufactured by Genotek, Inc. (Ottawa, ON, Canada). Those 
who agreed to test where mailed a saliva kit with instructions 
to complete and return to the study team using a postage-paid 
return envelope. Altogether, 41.9% (95% CI  =  38.2–45.6) of 
veterans returned their DNA kits to the study team.
statistical analyses
Descriptive statistics characterized the study sample. Likelihood 
of testing was analyzed both as an ordinal scale and collapsed 
into binary outcome variables (extremely likely, very likely, and 
likely = yes; not very likely, not likely at all = no) for PTSD and 
addiction, respectively, based on our statistical results. Since the 
dichotomous measures demonstrated the best statistical fit (33, 34), 
we present these results in the current paper. Next, multivariable 
logistic regressions (33), using stepwise backwards elimination 
were used with the p-value ≥0.05 for variable elimination in order 
to identify the best predictor variables associated with the likeli-
hood of proving a DNA sample for testing. Our candidate predic-
tor variables included multiple tours, poor/fair current health, 
high combat exposure, age, education, race, sex, being employed, 
having health insurance, having current PTSD, having current 
depression, using the VA for health care, having a positive current 
screen for alcohol dependence, using mental health services in 
past year, a history of concussion, using psychotropic medications 
in past year, using painkillers in past year, and returning the DNA 
sample at follow-up. Verbatim responses were manually coded 
by study staff and grouped categorically. “Don’t know” responses 
for the testing questions (<1%) were deleted for the purposes of 
regression analyses. Statistical analyses were conducted using 
Stata, version 13.1 (Stata Corp, College Station, TX, USA, 2014).
resUlTs
sample
Most veterans were between 40 and 64 years old (59.3%), male sex 
(95.9%), white race (93.3%), married (79.6%), had some college 
or higher education (57%), had health insurance (96.3%), were 
Vietnam veterans (72%), and a significant number (40.4%) cur-
rently used the VA health-care system (Table 1). The majority had 
a history of cigarette smoking (72.1%), and approximately 12% 
had a recent history of alcohol misuse (heavy drinking, 11.9%; 
positive alcohol dependence results on the CAGE scale, 12.4%).
Mental health history
A significant number of veterans were classified as having high 
combat exposure (21.1%), lifetime PTSD (9.6%), lifetime major 
depression (18.4%), poor or fair current health (31.6%), and 
having used prescription opioids in the past 12 months (13.9%). 
Approximately 20% of veterans were taking psychotropic medi-
cations (20.6%), had a recent mental health-related visit (21.9%), 
or had a history of concussion during their deployment (25.9%). 
In addition, more than 80% of veterans (82.3%) reported that 
being in combat was a major traumatic event for them (Table 1).
attitudes about genetic Testing
The majority of participants responded that they were “Not 
Likely at All,” or “Not Very Likely” to pursue genetic testing for 
TaBle 4 | Open-ended reasons given for interest/no interest in genetic 
testing for posttraumatic stress disorder (PTsD)/addiction.
reasons given for PTsD testing (n = 267)
•	 Curious/would like to know (25%)
•	 Self-benefit/knowledge (22%)
•	 Already diagnosed (15%)
•	 To help others (11%)
reasons given for no PTsD testing (n = 417)
•	 Does not have PTSD (31%)
•	 Unnecessary (19%)
•	 Older age (18%)
reasons given for addiction testing (n = 210)
•	 Self-benefit/knowledge (29%)
•	 Curious/would like to know (24%)
•	 Family history (13%)
reasons given for no addiction testing (n = 470)
•	 No addiction history (42%)
•	 Unnecessary (14%)
•	 Older age (13%)
TaBle 3 | stepwise logistic regressions predicting genetic testing 
(N = 700).a
Predictor variables Or (95% ci) p-Value
Yes, interest in genetic testing for posttraumatic stress disorder (PTsD)b,d
Age (years) 0.97 (0.96–0.99) <0.001
Current alcohol dependencec 2.12 (1.29–3.50) 0.003
Current PTSD 4.07 (1.80–9.20) 0.001
Mental health treatment past year 2.30 (1.51–3.52) <0.001
History of concussion during deployment 2.01 (1.37–2.93) <0.001
Used prescription painkillers in past year 1.69 (1.04–2.74) 0.033
Returned DNA sample 1.41 (1.01–1.99) 0.047
Yes, interest in genetic testing for addictionb,e
Age (years) 0.98 (0.97–0.99) 0.005
Current alcohol dependencec 1.85 (1.15–2.98) 0.011
Used psychotropic medications in past year 1.57 (1.04–2.35) 0.030
Used prescription painkillers in past year 1.73 (1.09–2.76) 0.021
History of concussion during deployment 1.71 (1.18–2.48) 0.004
aVariables assessed in backward stepwise logistic regression included serving multiple 
tours, having poor/fair health, high combat exposure, age, having some college or 
more, white race, male sex, employed full-time/part-time, having health insurance, 
current PTSD, current depression, currently using VA, having a positive screen for 
alcohol dependence, used mental health services in past year, having history of 
concussion, used psychotropic medications in past year, used painkillers in past year, 
and return of the DNA sample at follow-up. Variables with p ≥ 0.05 were removed from 
the analysis.
bYes = extremely likely, very likely, likely. No = not very likely, not likely at all.
cCAGE questionnaire (29).
dArea under ROC = 0.71; Hosmer–Lemeshow χ2 = 5.72, df = 8, p = 0.68; Pseudo 
R2 = 0.12.
eArea under ROC = 0.65; Hosmer–Lemeshow χ2 = 8.79, df = 8, p = 0.36; Pseudo 
R2 = 0.05.
TaBle 2 | Veterans’ interest in genetic testing for posttraumatic stress 
disorder (PTsD) and addiction (N = 700).
Testing interest/attitudes n (%) Yes/no, n (%)a
genetic testing for PTsD
Extremely likely 75 (10.7) Yes, 270 (38.6)
Very likely 77 (11.0)
Likely 118 (16.9)
Not very likely 93 (13.3) No, 427 (61.7)
Not likely at all 334 (47.4)
Don’t know/uncertain 3 (0.4)
genetic testing for addiction
Extremely likely 60 (8.6) Yes, 213 (30.4)
Very likely 54 (7.7)
Likely 99 (14.1)
Not very likely 87 (12.4) No, 481 (68.7)
Not likely at all 394 (56.3)
Don’t know/uncertain 6 (0.9)
Would liked to have known genetic results
Before deployment 181 (25.9)
After deployment 109 (15.6)
Neither before or after deployment 410 (58.6)
aYes = extremely likely, very likely, and likely. No = not very likely, not likely at all.
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PTSD (61.7%, Table  2) or for addiction (68.7%). Additionally, 
25.9% would have wanted to know about their genetic risk before 
deployment, 15.6% after deployment and 58.6% did not want 
to know their genetic risk before or after deployment (Table 2). 
While bivariate associations were found for current PTSD and 
addiction and the likelihood of testing based on Spearman cor-
rections (p < 0.001 for PTSD; p = 0.001 for addiction), the ordinal 
logistic regression results for these analyses fit poorly (Pseudo 
R2 = 2% for addiction; Pseudo R2 = 6% for PTSD). Consequently, 
we collapsed these results into binary “yes/no” measures and used 
logistic regressions for these analyses.
In veterans who did endorse interest in genetic testing for 
PTSD or addiction, the final stepwise logistic regression models 
found seven significant predictors for the likelihood of PTSD test-
ing and five predictors for addiction testing (Table 3). For PTSD 
testing, receiving recent mental health treatment (OR =  2.30, 
CI =  1.51–3.52,p <  0.001), history of concussion (OR =  2.01, 
CI =  1.37–2.93, p <  0.001), younger age (OR =  0.97, OR = 
0.96–0.99, p < 0.001), current PTSD (OR = 4.07, CI = 1.80–9.20, 
p = 0.001), current alcohol dependence (OR = 2.12, CI = 1.29–3.50, 
p = 0.003), use of opioids for pain (OR = 1.69, CI = 1.04–2.74, 
p = 0.033), and returning the DNA sample at follow-up (OR = 1.41, 
CI = 1.01–1.99, p = 0.047) were associated with the likelihood of 
genetic testing for PTSD at baseline. For addiction testing, history 
of concussion (OR = 1.71, CI = 1.18–2.48, p = 0.004), younger 
age (OR = 0.98, CI = 0.97–0.99, p = 0.005), currently taking psy-
chotropic medications (OR = 1.57, CI = 1.04–2.35, p = 0.030), 
current alcohol dependence (OR  =  1.85, CI  =  1.15–2.98, 
p = 0.011), and the use of prescription opioid painkillers in the 
past year (OR = 1.73, CI = 1.09–2.76, p = 0.021) were associated 
with the likelihood of genetic testing for addiction.
The results for the open-ended reasons given for both 
interest in and no interest in genetic testing for PTSD and 
addiction, respectively, are shown in Table  4. Reasons given 
for interest in genetic testing for both PTSD and addiction 
were mostly related to self-benefit and gaining additional 
knowledge (for PTSD, 25  +  22  =  47%; for addiction, 
29 +  24 =  53%). Reasons given for not testing are related to 
not having the condition or being reported as unnecessary 
(for PTSD, 31 + 19 = 50%; for addiction 42 + 14 = 56%). Concerns 
about privacy, confidentiality, discrimination, insurance cover-
age, etc., were not mentioned by the veterans.
5Lent et al. Genetic Testing
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DiscUssiOn
The principal study finding was that the majority of veterans were 
not interested in hypothetical genetic risk testing for PTSD (62%) 
or addiction (69%) at baseline. Most veterans (58.6%) reported 
that they would not want to know their genetic status either before 
or after deployment. The most frequent reasons for lack of inter-
est were not feeling at risk for these disorders and questioning 
the utility of genetic testing. Participants did not mention trust, 
ethical issues, or concern about employment. However, the 
majority of the veterans surveyed (55.3%) were not employed and 
were over 40 years old (90.6%). In addition, 96.3% reported cur-
rently having insurance coverage. Previously, challenges trusting 
researchers, privacy, discrimination concerns, and questions as 
to how genetic information would assist in psychiatric treatment 
were cited as reasons for testing hesitancy (5, 7).
Having current PTSD increased the likelihood of interest in 
genetic testing for PTSD fourfold (OR = 4.07). Recent mental 
health treatment, younger age, a history of concussion, a positive 
screen for alcohol dependence, a use of opioid pain medicines, 
and having returned the DNA sample at the follow-up, also 
was associated with interest in genetic testing for PTSD. Our 
findings differ from a previous study that found veterans in the 
VA system with PTSD expressed less favorable attitudes toward 
genetic testing than those without PTSD (7). Our larger sample 
size, older cohort, and our non-VA-based sample may account 
for the differences in results. For addiction, history of concus-
sion during deployment, younger age, taking psychotropic 
medications, a positive alcohol dependence screen, and recent 
use of opioids for pain were associated with increased interest 
in testing.
Genetic testing for psychiatric disorder risk would be most 
useful if testing occurred before the onset of symptoms, or 
specifically in veterans, before combat exposure. Testing has the 
potential to promote the practice of precision medicine (36) by 
informing prevention approaches at the individual level. Early 
testing could identify and target individuals at high risk via pro-
grams that include psychoeducation and heightened surveillance 
(37). However, participants in our study expressed little interest 
in genetic testing for two psychiatric disorders, citing often that 
they did not have that problem or condition. Future studies could 
evaluate whether interest in genetic testing for PTSD or addiction 
increases when tests are available to the patient or occurs at a 
younger age. When participants did endorse interest in genetic 
testing, reasons cited were most commonly for self-benefit and 
gains in knowledge. Highlighting these potential benefits of test-
ing could improve interest and participation. Also noteworthy 
is that the current study was a hypothetical assessment, since no 
genetic testing was actually available at the time of the baseline 
survey.
Genetic counseling, including education surrounding the 
clinical utility of genetic testing and the protections afforded by the 
Genetic Information Non-discrimination Act (38), may increase 
interest in testing; however, privacy and discrimination were not 
issues for veterans in the current study. Moreover, counseling 
may move patients closer toward acceptance of these disorders, 
leading to greater treatment-seeking behaviors (39). Counseling 
prior to testing can help to mediate misconceptions and fears 
surrounding uncertainty (40), perceived risk (41, 42), and stigma 
(43) and improve knowledge about causes of psychiatric disorders 
(41, 43). However, for conditions such as PTSD and addiction, 
which are complex and multifactorial disorders, genetic coun-
seling is limited at this time because the genetic variants known 
to date only explain a small percentage of the phenotypic variance 
(37, 44). Nevertheless, the epidemiology, biology, diagnosis, asso-
ciated comorbidity, and PTSD treatment options are considered 
well understood at this time (24, 26, 45, 46).
To date, our study is the largest investigation of attitudes 
toward psychiatric genetic testing and included individuals with 
and without psychiatric disorders who were not already engaged 
in genetic testing. The prevalence of psychiatric disorders in our 
community-based veteran sample resembled the general U.S. 
population more than many VA-based cohorts (18), potentially 
expanding the applicability of our findings. One limitation of 
this study was that our cohort was largely homogenous (>90% 
male, White, and older) Vietnam-era veterans (72%), which 
may not represent younger or female veterans’ views toward 
genetic testing for PTSD and addiction. Future studies should 
include more diversity and evaluate a wider range of psychiatric 
disorders.
In summary, the majority of veterans did not express interest 
in genetic testing for PTSD or addiction, two psychiatric disor-
ders of particular relevance to this population and that are of high 
interest in the VA system and to the veteran community (18, 46). 
As prospective discoveries and subsequent advancements 
continue to improve genetic testing, a more comprehensive 
understanding of views regarding screening will become 
increasingly imperative to expand its clinical application. It is 
important to emphasize that PTSD, in particular, is not just 
another mental disorder for veterans but also a compensated 
medical condition associated with military service and war-
fighting worldwide.
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